These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14569130)

  • 1. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology.
    Giusti RM; Rutter JL; Duray PH; Freedman LS; Konichezky M; Fisher-Fischbein J; Greene MH; Maslansky B; Fischbein A; Gruber SB; Rennert G; Ronchetti RD; Hewitt SM; Struewing JP; Iscovich J
    J Med Genet; 2003 Oct; 40(10):787-92. PubMed ID: 14569130
    [No Abstract]   [Full Text] [Related]  

  • 2. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer.
    Hubert A; Peretz T; Manor O; Kaduri L; Wienberg N; Lerer I; Sagi M; Abeliovich D
    Am J Hum Genet; 1999 Sep; 65(3):921-4. PubMed ID: 10441598
    [No Abstract]   [Full Text] [Related]  

  • 3. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study.
    Drucker L; Stackievitz R; Shpitz B; Yarkoni S
    Anticancer Res; 2000; 20(1B):559-61. PubMed ID: 10769725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The I1307K APC polymorphism: prevalence in non-Ashkenazi Jews and evidence for a founder effect.
    Shtoyerman-Chen R; Friedman E; Figer A; Carmel M; Patael Y; Rath P; Fidder HH; Bar-Meir S; Theodor L
    Genet Test; 2001; 5(2):141-6. PubMed ID: 11551102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One less thing to worry about: the shrinking spectrum of tumors in BRCA founder mutation carriers.
    Garber JE; Syngal S
    J Natl Cancer Inst; 2004 Jan; 96(1):2-3. PubMed ID: 14709725
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.
    Kauff ND; Perez-Segura P; Robson ME; Scheuer L; Siegel B; Schluger A; Rapaport B; Frank TS; Nafa K; Ellis NA; Parmigiani G; Offit K
    J Med Genet; 2002 Aug; 39(8):611-4. PubMed ID: 12161607
    [No Abstract]   [Full Text] [Related]  

  • 10. Hereditary ovarian cancer in Ashkenazi Jews.
    Robles-Díaz L; Goldfrank DJ; Kauff ND; Robson M; Offit K
    Fam Cancer; 2004; 3(3-4):259-64. PubMed ID: 15516850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
    Foulkes WD; Narod SA; Swenerton K; Panabaker K; Gilbert L
    J Natl Cancer Inst; 2003 Nov; 95(21):1640. PubMed ID: 14600100
    [No Abstract]   [Full Text] [Related]  

  • 12. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
    Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
    Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
    Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
    Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
    Laitman Y; Simeonov M; Herskovitz L; Kushnir A; Shimon-Paluch S; Kaufman B; Zidan J; Friedman E
    Breast Cancer Res Treat; 2012 Jun; 133(3):1153-7. PubMed ID: 22399190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes.
    Smith M; Fawcett S; Sigalas E; Bell R; Devery S; Andrieska N; Winship I
    Fam Cancer; 2008; 7(2):119-24. PubMed ID: 17636421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
    Kreiss Y; Barak F; Baruch RG; Levy-Lahad E; Pras E; Friedman E
    Genet Test; 2000; 4(4):403-7. PubMed ID: 11216667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients.
    Orr-Urtreger A; Bar-Shira A; Bercovich D; Matarasso N; Rozovsky U; Rosner S; Soloviov S; Rennert G; Kadouri L; Hubert A; Rennert H; Matzkin H
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):474-9. PubMed ID: 16537704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.
    Rennert H; Bercovich D; Hubert A; Abeliovich D; Rozovsky U; Bar-Shira A; Soloviov S; Schreiber L; Matzkin H; Rennert G; Kadouri L; Peretz T; Yaron Y; Orr-Urtreger A
    Am J Hum Genet; 2002 Oct; 71(4):981-4. PubMed ID: 12145743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer.
    Dagan E
    Genet Test; 2008 Jun; 12(2):267-71. PubMed ID: 18439109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.